1. Home
  2. OVBC vs MGNX Comparison

OVBC vs MGNX Comparison

Compare OVBC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ohio Valley Banc Corp.

OVBC

Ohio Valley Banc Corp.

HOLD

Current Price

$48.15

Market Cap

208.5M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.91

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OVBC
MGNX
Founded
1872
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.5M
220.6M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
OVBC
MGNX
Price
$48.15
$3.91
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
28.6K
1.3M
Earning Date
04-28-2026
05-08-2026
Dividend Yield
2.22%
N/A
EPS Growth
42.67
N/A
EPS
0.91
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
$52.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.51
$1.19
52 Week High
$50.68
$4.64

Technical Indicators

Market Signals
Indicator
OVBC
MGNX
Relative Strength Index (RSI) 61.14 49.67
Support Level $44.63 $1.49
Resistance Level $50.68 $4.64
Average True Range (ATR) 1.34 0.27
MACD 0.05 -0.06
Stochastic Oscillator 62.62 2.60

Price Performance

Historical Comparison
OVBC
MGNX

About OVBC Ohio Valley Banc Corp.

Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: